Genotype MTBDRplus 检测中 rpoB 探针杂交缺失识别「争议」利福平突变
研究对 275 株结核分枝杆菌用 Genotype MTBDRplus 检测,发现 15 株(6%)不与 rpoB 野生型或突变探针杂交。仅依赖 MGIT 960 药敏可能漏检约 20%(3/15)的耐药株。
要点
- 仅靠 MGIT 960 药敏可能漏检约 20%(3/15)此类耐药株。
- 同一 His526Leu 突变可对应敏感或耐药表型,需结合测序判断。
核心结论
- Genotype MTBDRplus 仅凭 rpoB 野生型探针杂交缺失判定利福平耐药,可识别重要耐药株。
- 约 20%(3/15)此类菌株仅靠 MGIT 960 药敏会被漏检。
研究设计与样本
- 研究纳入 275 株结核分枝杆菌,用 Genotype MTBDRplus 检测筛选杂交缺失菌株。
- 对筛选菌株进行测序,并用 Bactec MGIT 960 系统测定 MIC。
主要发现
- 275 株中 15 株(6%)出现 rpoB 探针杂交缺失。
- 测序显示杂交缺失由「争议」利福平突变所致。
- 一株敏感表型菌株与另一耐药表型菌株均携带 His526Leu 突变。
关键数值与推荐
- 利福平耐药表型定义为 MIC > 1 μg/mL(MGIT 960 测定)。
- Genotype MTBDRplus 推荐仅凭 rpoB 野生型探针杂交缺失即判定利福平耐药。
临床怎么用
- 对 Genotype MTBDRplus 显示 rpoB 探针杂交缺失的菌株,应按利福平耐药处理并进一步测序确认突变。
- 不应仅依赖 MGIT 960 药敏结果排除此类菌株的利福平耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mycobacterium tuberculosis isolates that fail to hybridize to at least one rpoB wild-type or any mutation probe on the Genotype MTBDRplus strip are assumed to be rifampicin-resistant. However, the precise mutation(s) are unknown. We sought to identify the mutations in isolates with such hybridization patterns and determine if the mutations are associated with resistance to rifampicin. METHODS: In this study, 275 M. tuberculosis isolates were screened with the Genotype MTBDRplus assay to identify isolates with the hybridization pattern. These isolates were sequenced and their minimum inhibitory concentrations (MIC) determined using the Bactec MGIT 960 system. RESULTS: Among the 275 isolates tested, 15 (6%) isolates with the hybridization pattern were identified. Sequencing showed that failure to hybridize to rpoB wild-type probes resulted from the presence of 'disputed' rifampicin mutations, which are mutations not always associated with a rifampicin-resistant phenotype. All, except 3/15, isolates had a rifampicin-resistant phenotype (MIC > 1 μg/mL). One of the three isolates with a rifampicin-susceptible phenotype had the same mutation at position 526 (His526Leu) as another isolate that had a rifampicin-resistant phenotype. CONCLUSION: The recommendation of the Genotype MTBDRplus assay to assume rifampicin resistance based solely on failure to hybridize to rpoB wild-type probe allows the identification of important RIF-resistant isolates. About 20% (3/15) of such isolates could be missed by relying only on the standard MGIT 960 DST assay for drug susceptibility testing.
引用
- Abanda NN, Djieugoué JY, Khadka VS, et al. Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations. Clin Microbiol Infect. 2017. PMID: 29217277. doi:10.1016/j.cmi.2017.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。